Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC351 (Cialis) for Raynaud's and Sexual Dysfunction in Scleroderma
NCT00707187Phase 2Completed
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Start
- Jul 2001
- Primary completion
- Jul 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tadalafil in Raynaud phenomenon and female sexual dysfunction (FSD) (2 arms), sponsored by University of Medicine and Dentistry of New Jersey. Primary endpoint: Number of Raynaud attacks at 16 weeks. Started Jul 2001; status: completed.
02
Drugs
tadalafil
03
Conditions
Raynaud phenomenonfemale sexual dysfunction (FSD)
Beyond the preview
Go deeper on NCT00707187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00707187.